Lantern Pharma
LTRN
30 hedge funds and large institutions have $9.89M invested in Lantern Pharma in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 8 closing their positions.
538% more call options, than puts
Call options by funds: $102K | Put options by funds: $16K
39% more capital invested
Capital invested by funds: $7.11M → $9.89M (+$2.78M)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0.19% more ownership
Funds ownership: 20.87% → 21.06% (+0.19%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less funds holding
Funds holding: 35 → 30 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$163K |
| 2 |
CM
CM Management
Gulf Breeze,
Florida
|
+$104K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$84.8K |
| 4 |
Two Sigma Investments
New York
|
+$67K |
| 5 |
Renaissance Technologies
New York
|
+$39.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BIOS Capital Management
Fort Worth,
Texas
|
-$251K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$39.9K |
| 3 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$38.5K |
| 4 |
SA
Sanctuary Advisors
Indianapolis,
Indiana
|
-$31.6K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$13.6K |
LTRN Hedge Fund Activity: Q3 2025 in Review
30 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q3 2025, worth a combined $9.89M — up 39% from $7.11M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of LTRN and 3 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 9 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $163K. The largest seller was BIOS Capital Management, cutting an estimated $251K.
- 30 institutional investors held Lantern Pharma (LTRN) as of Q3 2025, down from 35 in Q2 2025.
- Funds reported $9.89M of Lantern Pharma stock for Q3 2025, up 39% quarter-over-quarter.
- 3 funds opened new Lantern Pharma positions in Q3 2025 and 8 closed out, a net change of -5 holders.
- The largest Lantern Pharma buyer in Q3 2025 was Susquehanna International Group, an estimated $163K added.
- The largest Lantern Pharma seller in Q3 2025 was BIOS Capital Management, an estimated $251K sold.
Based on aggregated 13F filings for Q3 2025.